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Summary
Objective: The addition of exogenous high molecular weight hyaluronic acid (HA) reverses cartilage damage caused by fibronectin fragments
(Fn-fs) added to explant cultures of bovine and human cartilage and by Fn-fs in an experimental in vivo model of rabbit knee joint damage.
Our objective was to test whether HA was also effective in an IL-1 damage model and whether this repair was stable and occurred in older
bovine cartilage.
Design: Bovine cartilage explants from 18-month-old or 6-year-old bovines in 10% serum/Dulbecco’s modified Eagle’s medium were
exposed to Fn-f or to IL-1 and the ability of 1 mg/ml HA of 800 kDa to block damage or promote restoration of proteoglycan (PG) after the
damage was measured. The damage phase as well as the exposure to HA were varied.
Results: Exposure of exogenous HA decreased Fn-f-mediated damage, but did not decrease IL-1β-induced cartilage damage. If explants
from 18-month-old bovines were damaged by a 7-day exposure to Fn-f or IL-1β and then exposed for 7 days to HA, PG was restored. This
reparative activity persisted up to 4 weeks after the removal of HA from the culture medium. The restoration of PG did not occur in 0.1%
serum-free cultures, was less when the exposure to the Fn-f was doubled and failed when exposure to IL-1β was doubled. In explants from
6-year-old bovines damaged with IL-1β for 7 days, HA fully restored PG content to normal levels.
Conclusions: The reparative activities of HA occur not only in a Fn-f damage model, but also in an IL-1 damage model and occur with older
bovine cartilage.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
Hyaluronic acid or hyaluronan (HA), has been tested as a
therapeutic intervention in the treatment of osteoarthritis
(OA)1. Intra-articular HA treatment of the knee of patients
with OA has been shown to reduce painful symptoms and
improve joint mobility2–6. One report suggested that re-
peated intra-articular injections of HA weakly affect the
structural progression of OA in clinical patients7; however,
that conclusion will need to be strengthened with further
studies. In contrast to the reports of efficacy2–6, a recent
placebo-controlled trial failed to show positive results8.
Further, the results of a study that showed that HA reduced
one parameter of pain when compared with saline controls9
or with low molecular weight HA forms10, have been
challenged11. The complexities of interpretation of these
clinical trials and discussion of limitations of some of these
studies have been reviewed12.
Investigations of the effects of HA in animal models have
been less controversial. It has been shown in a Pond–Nuki
canine model, which involves severance and resection of
the anterior cruciate ligament, that HA causes significant
reduction of cartilaginous lesions and delays progression of
cartilage degradation13. In another anterior cruciate liga-
ment animal model in rabbits, HA decreased damage to
femoral condyles as measured by gross inspection, carti-
lage thickness, presence of collagen cross-links and hex-
osamine content14. In a bilateral canine osteoarthritis rabbit
model, HA was effective up to 6 months after injection and
prevented progression of OA15. HA also reduced histo-
pathology in a partial menisectomy model of OA in rabbit
knee16. In another partial meniscectomy rabbit model, HA
enhanced meniscal regeneration and inhibited cartilage
degeneration as long as 6 months post-surgery, suggesting
a long-term effect. In this study, there was a trend toward
increased proteoglycan (PG) content and less morpho-
logical degradation in HA-treated medial tibial articular
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cartilage17. In one study of a rabbit anterior cruciate liga-
ment transection model, the effect of HA on matrix metal-
loproteinases (MMPs) and cytokines was investigated. It
was found that HA reduced the grade of cartilage damage,
but did not block MMP production in cartilage, although it
did so in synovium18.
There have been many studies on the effects of HA in
simpler systems, for example in cartilage explant or
chondrocyte culture models. HA has also been shown to
block PG release caused by addition of catabolic cytokines
to cultured cartilage19–21; however, the mechanism is un-
known. One possible mechanism may be that HA acts as
an antioxidant and blocks reactive oxygen species involved
in cytokine pathways. In fact, HA was shown to inhibit
IL-1-induced superoxide anion in bovine chondrocytes22.
HA was also shown to increase PG synthesis in bovine
articular cartilage in the presence of IL-123.
In our investigation of the mechanisms by which HA
suppresses cartilage damage, we have utilized a model of
cartilage damage involving the ability of fibronectin frag-
ments (Fn-f) to damage cartilage explants24,25, through
elevation of catabolic cytokines26,27. This, in turn, elevates
levels of MMPs27–29 and also induces aggrecanase-like
cleavage30. This model has been reviewed31. A particular
useful feature of this model is that, while many of the
reported studies of HA utilize cytokine models, this model is
upstream of cytokine pathways and allows us to examine
the effects of HA in a more physiologic pathway of a more
complex nature.
In application of this model, our studies showed that HA
decreased the loss of cartilage PG in Fn-f-damaged carti-
lage in vitro, in both bovine32 and human cartilage33.
Further, in a counterpart Fn-f in vivo model in which
injection of Fn-f into rabbit knee joints causes marked PG
loss34,35, HA was also effective36. However, HA was also
found to restore PG lost from bovine32 and human carti-
lage33 explants previously damaged by Fn-f. These reports
were the first to show that HA had reparative activities in
vitro. Since the damaging agents were removed to test for
repair, there are likely mechanisms other than blocking
penetration of the mediator that would be required to
explain repair. This HA-mediated restoration of PG was
associated in human cartilage with enhanced PG synthe-
sis33. Whether or not the enhanced PG synthesis is due to
suppression of cytokine activities through anti-oxidant ac-
tivities or enhancement of anabolic pathways through other
mechanisms, is not yet clear.
In order to address the question as to whether HA acts to
block cytokine activities or affects other novel pathways, we
have investigated as to whether the effects of repair ob-
served in Fn-f-damaged cartilage apply to IL-1 damaged
cartilage as well. We have also investigated whether this
restoration of PG is persistent and, thus, of a useful nature,
and whether it occurs in older bovine cartilage.
Materials and methods
All common chemicals and reagents were from Sigma
Chemical Co. (St. Louis, MO). HA (800 kDa) and
5-aminofluoresceinated HA (800 kDa) were provided by
Seikagaku Corporation (Tokyo, Japan). Recombinant hu-
man IL-1β (cat. number: 201-LB) was from R & D Systems,
Inc. (Minneapolis, MN). Recombinant human IGF-1 was
from UBI (Lake Placid, NY).
ISOLATION OF FN-F
Fn-fs were generated from human Fn as described24.
The Fn-f tested was a well-characterized amino-terminal
29-kDa Fn-f that has been found to be the most potent24
and is referred to as the Fn-f.
CARTILAGE EXPLANT CULTURES
Cartilages from 18-month-old as well as cartilage from
older 6-year-old bovines were studied (Research 87,
Marlboro, MA). Only macroscopic-appearing normal carti-
lage was used in all the cases. Culturing of slices of bovine
metacarpophalangeal cartilage was performed as de-
scribed30 in Dulbecco’s modified Eagle’s medium (DMEM)
containing 50 U/ml penicillin–streptomycin in 10% fetal
bovine serum/DMEM or in DMEM alone, and with 50–
80 mg cartilage per 2 ml/well. The medium was changed
every other day. Each datum was based on assays of three
culture wells treated identically.
PG-CONTENT OF CARTILAGE AND ASSAYS OF PG DEPLETION
The total amount of PG/mg wet weight cartilage was
determined by assays with dimethylmethylene blue (DMB)
reagent after treatment of 50–80 mg of cartilage in 1.0 ml of
50 mM phosphate buffer, pH 6, containing 10 mM EDTA
and 10 mM cysteine, with 50 µg/ml papain for 16 h at 65°C
as originally described25–27. To assay PG, a volume of
0.8 ml DMB reagent, prepared as described24, was mixed
with 190 µl of 1.37 M GuHCl and 10 µl of test sample. After
2 min, a spectrophotometer was used to determine absorb-
ances at 525 and 595 nm, using water as a blank. The
ratios of 525 nm absorbance over 595 nm absorbance
were used to establish a standard curve with purified PG
and a standard curve of 0.5–3 µg/ml purified bovine PG
was used to estimate PG contents in the papain digests.
The data are reported as µg PG/mg wet weight cartilage
based on a mean and standard deviation (SD) of at least
three cartilage samples. The data were compared by
unpaired t test analysis. A P value <0.05 was considered
significant.
TESTS OF EFFECTS OF HA ON BLOCKING FN-F OR IL-1β-MEDIATED
DAMAGE, ON RESTORING PG AND ON STABILITY OF REPAIR
To test for blocking activity, to 10% serum/DMEM cul-
tures, HA was typically added to a final concentration of
1 mg/ml. After 4 h, the Fn-f was added to a final 0.1 µM
concentration or IL-1β was added to a final 10 ng/ml
concentration. Every 7 days during the 28 to 42-day culture
period, cartilage was removed, the dry weight was deter-
mined and the cartilage was subjected to assays of PG
content.
To test for restoration of PG, cartilage was cultured with
0.1 µM Fn-f or 10 ng/ml IL-1β for 7 or 14 days in 10%
serum/DMEM in order to remove about half of the total
cartilage matrix PG. At 7 or 14 days, HA was added to a
final 1 mg/ml concentration. Every 7 days, for up to 42
days, cartilage was removed for assays of total PG content.
To test for stability of repair, cartilage was cultured with
Fn-fs or IL-1β for 7 days as described before to deplete
about half of the cartilage PG and then cultured with
1 mg/ml HA in 10% serum/DMEM for an additional period.
The HA was then removed at various times, and cultur-
ing continued in 10% serum/DMEM alone. Slices were
removed for PG content analysis each of the 7 days.
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BINDING OF HA TO CARTILAGE
Fl-HA (provided by Seikagaku Corp, Tokyo, Japan) was
added at a final concentration of 1 mg/ml to cultured
18-month-old bovine cartilage in 10% serum/DMEM for 7
days. Cartilage was recovered, washed exhaustively with
DMEM and subjected to cryosectioning (10 µm). The sec-
tions were then mounted in glycerol on slides and visual-
ized with an Olympus BH-2 microscope equipped with
epifluorescence using appropriate filters for fluorescein. A
×10 objective and ×2 ocular were used to photograph with
400 ASA Kodak Tri-X film pushed to 1600 ASA with 4 min
per exposure.
Results
RESTORATION OF PG BY HA DID NOT REVERSE AFTER REMOVAL
OF HA FROM FN-F-DAMAGED CARTILAGE
We had shown earlier that 1 mg/ml HA blocked the
ability of the Fn-f to deplete PG content in cultures in 10%
serum/DMEM and that HA also partially restored PG to
normal or above levels by day 21 in cartilage first treated
with Fn-f32,33. In order to investigate the stability of HA-
mediated restoration of PG, cartilage was first treated with
Fn-fs for 7 days in 10% serum/DMEM to deplete PG, and
was then treated with 1 mg/ml HA for periods of 7, 14, 21
or 35 days during a 42-day culture period. As shown in
Fig. 1(A), 7 days of HA treatment (F [d0–7]; HA [d7–14]
curve) was sufficient for a full restoration of PG, and the
restoration was stable up to day 42 or up to 4 weeks after
the HA was removed. At days 14, 21, 28, 35 and 42, the
PG content for the F (d0–7); HA (d7–14) curve were
significantly different than Fn-f treatment at P values of
0.045, 0.01, 0.003, 0.002 and 0.001, respectively. The
curves for HA (d7–21) and HA (d7–42) were very similar
to the HA (d7–14) curve with similar levels of signifi-
cant difference when each was compared with Fn-f treat-
ment. PG content in the repair curves appeared to be
greater than control levels, but did not reach significant
difference.
In another set of experiments, the response of cartilage
exposed to Fn-f for twice as long, for 14 days, was
investigated. Figure 1(B) shows that restoration of PG to
control levels occurred after an exposure to HA for as short
a period as 7 days (F [d0–14]; HA [d14–28] curve) (P
0.18 for 7 days when experimental compared with control).
A decreased effect is suggested by the decrease in PG
content at day 35 for the days 14–28 HA treatment (P
0.14 for experimental vs control and P<0.005 for experi-
mental vs Fn-f). This decreased effect was also observed at
day 42.
When cartilage was damaged with Fn-f in the presence
of 0.1% serum present throughout the experiment, a
greater degree of PG depletion occurred, but HA, added at
day 7, did not promote restoration of PG (data not shown).
Therefore, either the greater degree of damage or the
lower concentration of serum components decreased the
potential for repair.
In other experiments, when cartilage was first damaged
by Fn-f and HA was substituted with 1 mg/ml methylcellu-
lose, with viscosity similar to that of HA, restoration of PG
did not occur (data not shown). Further, methylcellulose did
not block Fn-f-mediated damage.
HA REMAINED ASSOCIATED WITH CARTILAGE MATRIX DURING
CULTURE PERIOD
In order to determine as to how long cartilage treated
with HA retained the HA and where HA bound, Fl-HA was
added to the 10% serum/DMEM media of cultured cartilage
between day 0 and 7, and the excess Fl-HA was removed
at day 7. Sections were analyzed for fluorescence at
various time points. Figure 2 shows that in controls not
treated with HA (−HA) there was no detectable fluores-
cence. Ph shows a typical phase contrast of the control
tissue. C7, C14 and C28 show cartilage after treatment with
Fl-HA between day 0 and 7, and are then analyzed at days
7, 14 and 28. Similar cultures were also treated with Fn-f
between day 0 and 7 as well as Fl-HA, and the media Fl-HA
was removed as with the control cultures. F7, F14 and F28
show the respective Fn-f-treated sections. Note that fluor-
escence is still detected up to 21 days after removal of HA
Fig. 1. Effect of removal of HA from cultures of Fn-f-damaged and
PG-restored cartilage. (Panel A) Bovine cartilage was cultured in
10% serum/DMEM alone (Control) or with 100 nM Fn-f in 10%
serum/DMEM from day 0 to 7 to remove about half of the total
cartilage PG. At day 7, the media of some of the untreated cultures
were adjusted to HA alone (HA [d7–42]). The media of the
Fn-f-treated wells was changed to 10% serum/DMEM alone (Fn-f
[d0–7]) or to 1 mg/m HA in 10% serum/DMEM (Fn-f [d0–7]; HA
[d7–14 or d7–21 or d7–42]). PG content was measured every 7
days. (Panel B) Similar conditions as in panel A except the Fn-f
treatment was for 14 days, followed by HA treatment from day 14
to 28 or from day 14 to 42.
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from the culture media in either the HA control or Fn-f-
treated cartilage and that Fn-f treatment does not appear to
either enhance the amount of Fl-HA bound between day 0
and 7 or decrease the amount bound at a later time point.
In all the tissues, fluorescence was observed throughout
the full thickness.
HA DID NOT DECREASE DAMAGE BY IL-1β BUT DID REVERSE
DAMAGE CAUSED BY IL-1β IN THE ABSENCE OF HA
In order to determine whether the blocking and repara-
tive effects of HA were unique to Fn-f-mediated damage,
another catabolic mediator, IL-1β, was used as a test
Fig. 2. Visualization of Fl-HA in normal (C) and Fn-f (F)-damaged cartilage as a function of time—Fl-HA was incubated in 10% serum/DMEM
bovine cartilage cultures from day 0 to 7 and then removed. Sections were analyzed by fluorescence microscopy at days 7, 14 and 28.
Shown are control cultures (C) incubated with Fl-HA, but not with Fn-f and cartilage cultured with Fn-f and Fl-HA for days 0–7. The −HA
corresponds to no addition of Fl-HA. Ph is phase image of −HA section.
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agent. Figure 3(A) shows that preincubation of cartilage
with 1 mg/ml HA, followed by addition of IL-1β, resulted in a
major loss of PG by day 7 (P0.0002 for experimental vs
control), a loss similar to that of IL-1β alone (P0.02 for
experimental vs control). However, HA did facilitate restor-
ation of PG in cartilage first exposed to IL-1β for 7 days as
shown inFig. 3(B). Restoration occurred to levels that were
significantly greater than IL-1β-treated levels (P0.038,
0.0009, 0.001, 0.001 for IL-1 vs IL-1/HA treatment at days
14, 21, 28 and 35, respectively). The restored levels at
days 28 and 35 were also significantly greater than the
control untreated levels (P<0.03 and 0.02, respectively).
RESTORATION OF PG BY HA DID NOT OCCUR AFTER REMOVAL OF
HA FROM IL-1β-DAMAGED CARTILAGE IF THE DAMAGE PERIOD
WAS PROLONGED
The stability of restoration of PG in IL-1β-damaged
cartilage was investigated (Fig. 4). Panel A shows that
restoration of PG occurred after only a 14-day treatment
with HA (IL [d0–7]; HA [d7–14]) was significantly greater
than IL-1β treatment alone (P<0.04 at day 21). This degree
of restoration was stable through day 42 (P0.003 for IL-1β
vs IL-1β;HA at day 42). Restoration of PG was more
complete after HA treatment for 28 days (IL [d0–7]; HA
[d7–28] curve) and was at control levels at day 28 (P
0.8 when experimental compared with untreated control)
and above control levels at days 35 and 42 (P0.028,
0.0124, respectively). Similar results were observed with
half the concentration of IL-1β, 7.5 ng/ml (data not shown).
As with the earlier data, HA-treated cartilage, whether first
damaged or not, showed PG contents later in culture that
were greater than non-HA treated controls (P0.03, 0.015,
respectively, for days 35 and 42).
The effect of a longer damage period which would also
delay introduction of HA by an additional period was also
tested. As shown in Fig. 4(B), a longer treatment for 14
days with IL-1β prevented HA from causing a stable resto-
ration of PG. Addition of HA for 14 days, followed by its
removal, did not allow a regain of PG up through day 21. At
day 28, there was an increase in PG content with HA-
treated cartilage to a level indistinguishable from control
Fig. 3. Effect of HA on blocking depletion of PG and promoting
restoration of PG in IL-1β-treated explants. (Panel A) Conditions
were similar to those in Fig. 1(A), except 10 ng/ml IL-1β in 10%
serum/DMEM were used to damage rather than 100 nM 29-kDa
Fn-f. (Panel B) Conditions were similar to those in Fig. 1(B), except
repair was tested after treatment with 10 ng/ml IL-1β in 10%
serum/DMEM from day 0 to 7.
Fig. 4. Effect of removal of HA from cultures of IL-1β-damaged and
PG-restored cartilage. (Panel A) Bovine cartilage was cultured in
10% serum/DMEM alone (Control) or with 10 ng/ml IL-1β in 10%
serum/DMEM from day 0–7 to remove about half of the total
cartilage PG. At day 7, the media of some of the untreated cultures
were adjusted to HA alone (HA [d7–28]). The media of some of the
IL-1β-treated wells were changed to 10% serum/DMEM alone (IL-1
[d0–7]) or to 1 mg/m HA in 10% serum/DMEM (IL-1 [d0–7]; HA
[d7–14 or d7–28]). PG content was measured every 7 days. (Panel
B) Similar conditions as in panel A, except the IL-1β-treatment was
for 14 days, followed by HA treatment at days 14–28 or days
14–42.
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levels (P0.07 for both damage/HA curves). However, by
day 35, the attempted repair had failed and PG contents
were indistinguishable from IL-1β treatment (P>0.36 for
both compared with control). The repair curves remained at
damaged levels at day 42.
HA DID NOT BLOCK IL-1β-MEDIATED DAMAGE IN 6-YEAR-OLD
BOVINE CARTILAGE, BUT DID PROMOTE REPAIR TO THE SAME
LEVEL AS DID IGF-1
To test whether HA blocked IL-1β-mediated PG deple-
tion, cartilage was obtained from 6-year-old bovines and
cultured separately. Only normal looking cartilage, as as-
certained by gross macroscopic analysis, was used. The
cartilage did not have apparent fibrillation. Separate cultur-
ing was performed because of the greater potential for
variability of older cartilage. As shown in Fig. 5, the control
cartilages to which nothing was added, except for speci-
men D, showed a significant decrease in PG content by day
7 when treated with IL-1β. The P values for day 7 data for
specimens A–D, respectively, when control data were com-
pared with IL-1 (d0–7)-treated samples were 0.0045,
0.0001, 0.0002 and 0.096. HA was not effective in blocking
IL-1β-mediated PG depletion in any of the specimens, as
also shown earlier for the 18-month-old cartilage. The P
values for day 28 data for specimens A–D, respectively,
when IL-1 (d0–7) and IL-1β, HA (d0–28) data were com-
pared were 0.127, 0.20, 1.0 and >1.0, respectively.
However, when IL-1β was added for 7 days to deplete
PG and then removed and HA was added, there was
significant restoration of PG in the four different cartilage
specimens within 7 days of HA treatment. The P values for
day 14 data for specimens A–D, respectively, when IL-1
(d0–7) data were compared with IL-1 (d0–7); HA (d7–28)
treatment were 0.045, 0.0068, 0.03 and 0.042, respec-
tively. By day 21, restoration was almost to control levels of
PG. The P values for day 21 when control and HA-treated
data were compared were <0.17 for specimens A, B and C
and 0.08 for specimen D. By day 28, PG restoration was
more complete.
Two additional 6-year-old bovine sources showed similar
results (data not shown). In other experiments, treatment
with IL-1β for 14 days before HA treatment did not allow
significant restoration of PG (data not shown), as also
demonstrated for the cartilage explants from 18-month-old
bovines.
Fig. 5. Effect of HA on decreasing IL-1β-mediated damage in 6-year-old bovine cartilage and promoting repair—To test blocking activity,
cartilage from 6-year-old bovines was cultured in 10% serum/DMEM alone (Control) or with 10 ng/ml IL-1β in 10% serum/DMEM from day
0 to 7 (IL [d0–7]) or with both IL-1β and 1 mg/ml HA from day 0 to 28 (IL, HA [d0–28]). To test for repair, cartilage was cultured with 10 ng/ml
IL-1β from day 0 to 7, to remove PG and then incubated with 1 mg/ml HA in 10% serum/DMEM from day 7 to 28 (IL [d0–7]; HA [d7–28]).
Controls for continuous IL-1β for days 0–28 are not shown, but were similar to day 0–7 treatment. PG content was measured every 7 days.
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Since we have shown that IGF-1 has reparative activity
toward Fn-f-damaged cartilage37, we attempted to com-
pare the reparative effects of HA with that of IGF-1 in
IL-1-mediated damage. Separate cultures of 6-year-old
cartilage from two different bovines (A and B) were first
damaged with IL-1β for 7 days and then adjusted to
100 ng/ml IGF-1, as well as a combination of 1 mg/ml HA
and IGF-1. Figure 6 shows that by day 24 with specimen A,
HA, IGF-1 and a combination restored PG to control levels
(P>0.2 for experimental vs control). The combination was
not significantly better than HA or IGF-1 alone (P<0.2 for
combination vs HA or IGF-1). At day 32, the PG content in
control cartilage had decreased compared with day 24. At
day 32, each treatment enhanced PG content to levels
greater than control (P<0.02 for treatment vs control).
Similar trends were observed for specimen B.
Discussion
We have reported that high molecular weight HA can
suppress decreases in cartilage matrix PG content from
both bovine metacarpophalangeal cartilage32 and human
knee cartilage33 in the presence of Fn-fs, which we have
shown to cause chondrocytic chondrolysis. We have also
found that HA can promote restoration of PG in Fn-f-
damaged bovine or human cartilage32,33.
Our objectives were to determine whether blocking or
restoration of PG were unique to Fn-f-mediated damage or
would also occur in an IL-1β damage system. We have
reported that Fn-fs upregulate cytokines, such as IL-1β26,27
and, thus, one might expect that HA-mediated repair of
Fn-f-damaged cartilage should also be observed in an
IL-1β damage model. However, Fn-fs upregulate TNF-α
and IL-1β in a short-term pulse-like pattern, which leads to
a relatively short pulse of MMP activity26. Other catabolic
cytokines such as IL-1α and IL-6 are also upregulated26.
However, the enhanced MMP release does not occur
continuously. In contrast, in a typical IL-1β damage model,
IL-1β is added continuously, but little is known as to
whether MMP upregulation remains elevated during the
culture period. Thus, because IL-1β is often used for a
cartilage explant damage model, it was important for us to
determine whether HA would also be effective in an IL-1β
model.
We first confirmed that HA was effective in suppressing
PG depletion in Fn-f-cultured 18-month-old bovine cartilage
for up to 28 days and also in enhancing repair as we
reported32. Additionally, we also tested the stability of this
repair, which has not yet been reported. We also investi-
gated another parameter, the role of serum and found that
the restoration of PG did not occur if the serum was
lowered from 10 to 0.1%. Thus, serum appears to be
important in providing greater vitality for repair. This block-
ing activity or ability of HA to facilitate restoration of PG in
10% serum cultures was not due to a viscosity effect, as
shown by our experiments with methylcellulose. The activ-
ity was not due to interaction between HA and Fn-f, since
we reported earlier that HA and the Fn-f do not interact as
shown by gel filtration chromatography32. The reparative
activity also appeared to be stable in that the removal of HA
after only a 7-day exposure to the damaged cartilage still
allowed a full restoration of PG in Fn-f-damaged cartilage. It
should also be noted that the concentration of HA we have
used throughout these studies was 1 mg/ml. Since the
synovial fluid concentration of HA is 2–4 mg/ml, as re-
viewed12, we are not studying effects due to the use of
abnormally high concentrations of HA.
In order to provide an explanation for the stability of the
repair, we tested whether a brief 7-day exposure was
sufficient for binding of fluorescent HA and whether the HA
remained bound once the excess HA in the culture media
was removed. Fluorescence microscopy showed that the
HA that bound within a 7-day exposure period remained
bound to cartilage for up to 21 days, whether the cartilage
was exposed to Fn-f or not. Since a concentration of
1 mg/ml of fluorescent HA was used and the synovial fluid
concentration of HA is 2–4 mg/ml12, this binding was physio-
logic and not driven by an artificially high concentration of
HA. Further, the fluorescence appeared to penetrate
throughout the full thickness section of the cartilage and the
HA appeared to surround the cells. We had reported earlier
that most of the HA remained on the superficial cartilage
surface; however, more sensitive detection does show that
a very small fraction does become internalized. We have
no explanation for how HA of 800 000 can penetrate and
diffuse throughout the section. It is very possible that the
very small fraction of HA that does penetrate is degraded
and that this is the active fraction of HA. This will be difficult
Fig. 6. Comparison of HA and IGF-1 on promoting restoration
of PG in IL-1β-mediated damage in 6-year-old bovine cartilage—
Conditions similar to those in Fig. 5 were used to test for repair.
Cartilage was first treated with 10 ng/ml IL-1β for 7 days in 10%
serum/DMEM and was then treated with 1 mg/ml HA (HA) or
100 ng/ml IGF-1 (IGF-1) or a combination of the two (Both) from
day 7 to 32. A duplicate control curve for day 0 to 7 IL-1β treatment
is included.
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to demonstrate because of the relative difficulty in separat-
ing this small amount of HA from the surface-bound HA and
determining its mass. However, future experiments will
include work in that direction.
This observation of retention of HA within the cartilage
matrix for weeks after the initial treatment is also consistent
with our earlier report that a 1-day treatment with 1 mg/ml
HA decreased the effect of the Fn-f for up to 28 days32.
These collective results suggest that the effects of HA
persist after the excess is removed from the media and that
the reparative activity is not due to the solution phase HA in
the media, but rather to the bound HA. Thus, the efficacy of
HA in clinical studies should not be strictly dependent on
the synovial fluid concentration.
Interestingly, HA did not block IL-1β-mediated damage as
it did in Fn-f-mediated damage. This may be because the
29-kDa Fn-f used in this study can bind matrix components
such as PG, while the IL-1β would not be expected to have
specific binding affinity for matrix components. We have
shown that treatment of cartilage with HA decreases pen-
etration of Fn-f into cartilage tissue and that this cannot be
due to interaction between HA and Fn-f since complexes
were not observed by gel filtration chromatography32. We
did not test whether or not HA blocked penetration of IL-1β
since others have shown that HA does not alter effects of
IL-1 on cartilage matrix synthesis, and this may suggest
that HA does not block penetration of IL-120,21.
Most importantly, this work does show that HA can be
effective in a cytokine model in terms of restoration of PG
and, thus, this work supports the notion of a general effect
of HA on cartilage repair. Since HA did not block IL-1-
mediated damage, but promoted repair, this may suggest
that the potential physical effect of HA on decreasing
penetration of Fn-f, as we have reported32,33, probably
plays only a small role in the overall chondroprotective
effect of HA. While it can be argued that HA does block
penetration of Fn-f and decreases damage, the most
important activity of HA may be more general, and may be
due to the enhancement of reparative processes.
Nonetheless, since HA helped restore PG in both Fn-f
and IL-1β-damaged cartilage, it is likely that the reparative
mechanism does not involve unique synergistic interaction
with elements of a Fn-f damage or repair pathway, unless
these elements would be similar in an IL-1β system. It is
more likely that HA has direct effects on catabolic and/or
anabolic pathways. It was interesting to note that a short
7-day exposure to HA was sufficient to initiate these effects
in either the Fn-f or IL-1 models. Thus, HA triggers anabolic
pathways or suppresses catabolic pathways that continue
after removal of the bulk of the HA, consistent with our
visualization of Fl-HA in cartilage weeks after removal of
HA from the media.
When cartilage was cultured with IL-1β for 14 days, the
restoration of PG was not stable and certainly not as stable
as with prolonged Fn-f treatment. While we cannot interpret
whether this relative failure to restore PG stably is due to
prolonged deleterious effects of IL-1β treatment or due to
the delay of introduction of HA, it does point out that there
may be differences in our Fn-f model vs cytokine models. In
our Fn-f models, a cytokine pulse is caused, which may be
milder than the effects of continuous incubation with cyto-
kines. Since restoration of PG was more complete with
Fn-f-damaged cartilage, also with a delayed introduction
of HA, it is likely that the lesser restoration of PG with
prolonged IL-1β treatment is not due to the timing of
introduction of HA, but rather due to the severity of the
treatment. It should be noted that we have shown that
continuous treatment with Fn-f does not decrease PG
content38–40, and that the chondrocytes respond to Fn-f
treatment initially with reduced PG and general protein
synthesis, but later show elevated rates of synthesis, which
by 28 days in culture, return to control values38–40. There-
fore, it is unlikely that the Fn-f have caused reduced cell
vitality during the more prolonged treatment. However, we
did not test the effect of prolonged treatment with IL-1β on
cell vitality.
Another interesting observation was that HA appeared to
enhance PG content to above normal levels. Such an effect
is not without precedent. We have observed this effect with
other agents as well, including antioxidants37,41,42 or syn-
thetic peptides that mimic the cell-binding domain of Fn43
or the growth factor, OP-144. Further, addition of lower
concentrations of Fn-f to cartilage explants, which cause
enhanced PG synthesis, also enhances PG content to
above normal levels38–40.
The observation that HA was effective on IL-1β-treated
6-year-old cartilage explants, though perhaps to a lesser
degree, was encouraging since older cartilage is thought to
be less capable of repair. In fact, it has been shown that
bovine cartilages of this age are much less responsive to
growth factors such as IGF-145. Nonetheless, IGF-1 as well
as HA, potently enhanced restoration of PG.
In summary, HA has been shown to be effective not only
in a Fn-f model, but also in a cytokine model of cartilage
damage. It has also been found to be effective long after
the excess solution form of HA is removed from the
cultures, and is also effective on older cartilage. Collec-
tively, these data add to a growing literature on the efficacy
of HA in in vitro models of cartilage damage. However,
caution should be exercised in extrapolating our results to
expectations of efficacy in clinical trials since the joint
presents a much more complex milieu than our culture
conditions.
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